In the middle of an R&D shakeup, Novartis makes a $300M investment in early-stage biologics research tech
Within the past six months, Novartis has tapped new leaders for both its research arm and development organization. But Vas Narasimhan isn’t done revamping the global R&D org.
While his previous moves involved big cuts, this time the CEO is looking to add something: a $300 million initiative to bolster Novartis’ capacity and capabilities for “early technical development of biologics.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.